# A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

> **NCT07490990** · — · NOT_YET_RECRUITING · sponsor: **West China Hospital** · enrollment: 30 (estimated)

## Conditions studied

- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Disitamab vedotin + Sintilimab + Multimodality radiotherapy

## Key facts

- **NCT ID:** NCT07490990
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07490990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07490990, "A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07490990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*